Nutex Health director awarded 603 RSUs

Nutex Health, Inc. director Scott J. Saunders reported receiving an equity award in the form of restricted stock units.

Rhea-AI Filing Summary

Nutex Health, Inc. director Scott J. Saunders reported receiving an equity award in the form of restricted stock units. On July 14, 2025, he was granted 603 RSUs at a price of $0 per unit, each representing the right to receive one share of Nutex common stock upon vesting.

These RSUs vest 100% on July 14, 2026. If Saunders leaves the company without cause before that vesting date, the award will vest on a pro-rata basis according to the actual time he remained in service with the company.

Insider Trade Summary

Grant/Award: 603 shares

Grant/Award 1 txn

Insider Saunders Scott J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units (RSUs)	603	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units (RSUs) — 603 contracts (Direct)

Footnotes (2)

1. F1. Each RSU represents a contingence right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.
2. F2. On July 14, 2025, the Reporting Person was granted 603 RSUs, which vest 100% on July 14, 2026. If the Reporting Person leaves service with Company without cause, during the vesting period, the RSUs shall vest on a pro-rata basis for the actual time in service for the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nutex Health (NUTX) report for Scott J. Saunders?

Nutex Health reported that director Scott J. Saunders received an award of 603 restricted stock units (RSUs) on July 14, 2025. Each RSU represents the right to receive one share of Nutex common stock upon vesting, providing equity-based compensation.

How many restricted stock units did the Nutex Health director receive?

The Nutex Health director received 603 restricted stock units (RSUs). These units were granted at a price of $0 per RSU and each RSU converts into one share of Nutex common stock once the vesting conditions are met, increasing his potential share ownership.

When do the 603 RSUs granted by Nutex Health to its director vest?

The 603 RSUs granted to the Nutex Health director vest 100% on July 14, 2026. This means all units convert into common shares on that date if he remains in service, aligning his compensation with the company’s longer-term performance.

What happens to the Nutex Health RSUs if the director leaves before July 14, 2026?

If the director leaves Nutex Health without cause before July 14, 2026, the 603 RSUs vest on a pro-rata basis. Vesting is adjusted to match the actual time he remained in service during the vesting period, rather than forfeiting the entire award.

What does each Nutex Health RSU granted to the director represent?

Each Nutex Health RSU represents a contingent right to receive one share of the company’s common stock, with a par value of $0.001. The shares are delivered only when the RSUs vest, linking the director’s compensation to share-based value.

Is the Nutex Health director’s RSU award reported as directly owned?

Yes. The filing shows the 603 RSUs as directly owned by the reporting person following the transaction. Direct ownership indicates the award is attributed personally to the director, rather than through an intermediary entity or indirect holding structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 01:04 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saunders Scott J

(Last) (First) (Middle)

C/O NUTEX HEALTH INC.

6030 S. RICE AVE. SUITE C

(Street)

HOUSTON TX 77081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nutex Health, Inc. [ NUTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSUs)	$0(1)	07/14/2025		A		603(1)		07/14/2026(2)	07/14/2026(2)	Common Stock	603	$0	603	D

Explanation of Responses:

1. Each RSU represents a contingence right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.

2. On July 14, 2025, the Reporting Person was granted 603 RSUs, which vest 100% on July 14, 2026. If the Reporting Person leaves service with Company without cause, during the vesting period, the RSUs shall vest on a pro-rata basis for the actual time in service for the Company.

	/s/ Scott J. Saunders	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.